The 7th B2B Uro-Oncology: GU Cancers Triad Meeting will feature the latest innovations, multidisciplinary practices, and scientific advances in the management of bladder, kidney, and prostate cancers. Mark your calendar on October 31, 2025, for this unique meeting, held in conjunction with the 45th SIU Annual Congress in Edinburgh, Scotland.

About the B2B Uro-Oncology: GU Cancers Triad  

The rapidly evolving treatment landscape for bladder, kidney, and prostate cancers poses a challenge for urologists, medical oncologists, and radiation oncologists alike. In managing these GU cancers, physicians need to keep up with new data on therapeutic options, provide individualized care through a multidisciplinary approach, and use optimal treatment sequence or combinations while effectively managing side effects.

Join the prestigious B2B Scientific Programme Committee and world-renowned thought leaders for a one-day programme dedicated to the latest advances and evidence-based practices in GU cancer care.

Learning Objectives:

• Evaluate the benefits, risks, and limitations of various treatment options across the management continuum in prostate cancer, bladder cancer, and kidney cancer.
• Recognize the role of imaging and genetic markers in guiding treatment decision-making.
• Analyze the efficacy and safety of emerging therapeutic approaches for the management of GU cancers based on current clinical data.
• Recall strategies to identify, manage, and mitigate adverse events related to systemic treatment.
• Discuss the importance of personalized medicine, based on treatment costs and patient preference, while minimizing toxicity and maximizing efficacy.